PriceTargets.com logo

Telix Pharmaceuticals Limited American Depositary Shares - TLX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 27.17%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$17.30 As of 03/14/2025 05:00 PM ET
▲ +0.31 (1.82%)

This chart shows the closing price for TLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Telix Pharmaceuticals Limited American Depositary Shares Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLX

Analyst Price Target is $22.00
▲ +27.17% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Telix Pharmaceuticals Limited American Depositary Shares in the last 3 months. The average price target is $22.00, with a high forecast of $22.00 and a low forecast of $22.00. The average price target represents a 27.17% upside from the last price of $17.30.

This chart shows the closing price for TLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Telix Pharmaceuticals Limited American Depositary Shares. This rating changed within the last month from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/12/2025William BlairReiterated RatingOutperform
1/27/2025UBS GroupBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
11/19/2024William BlairUpgradeStrong-Buy
11/15/2024UBS GroupInitiated CoverageBuy$21.00
(Data available from 3/15/2020 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/14/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/13/2025
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/12/2025
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/14/2025

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Telix Pharmaceuticals Limited American Depositary Shares logo
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Read More

Today's Range

Now: $17.30
Low: $17.02
High: $17.38

50 Day Range

MA: $17.47
Low: $14.56
High: $20.93

52 Week Range

Now: $17.30
Low: $14.01
High: $30.36

Volume

15,903 shs

Average Volume

27,667 shs

Market Capitalization

$5.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Telix Pharmaceuticals Limited American Depositary Shares?

The following Wall Street research analysts have issued research reports on Telix Pharmaceuticals Limited American Depositary Shares in the last twelve months: UBS Group AG, and William Blair.
View the latest analyst ratings for TLX.

What is the current price target for Telix Pharmaceuticals Limited American Depositary Shares?

0 Wall Street analysts have set twelve-month price targets for Telix Pharmaceuticals Limited American Depositary Shares in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 27.2%. UBS Group AG has the highest price target set, predicting TLX will reach $22.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $22.00 for Telix Pharmaceuticals Limited American Depositary Shares in the next year.
View the latest price targets for TLX.

What is the current consensus analyst rating for Telix Pharmaceuticals Limited American Depositary Shares?

Telix Pharmaceuticals Limited American Depositary Shares currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TLX will outperform the market and that investors should add to their positions of Telix Pharmaceuticals Limited American Depositary Shares.
View the latest ratings for TLX.

What other companies compete with Telix Pharmaceuticals Limited American Depositary Shares?

Other companies that are similar to Telix Pharmaceuticals Limited American Depositary Shares include Beigene, Teva Pharmaceutical Industries, Genmab A/S, Intra-Cellular Therapies and Moderna. Learn More about companies similar to Telix Pharmaceuticals Limited American Depositary Shares.

How do I contact Telix Pharmaceuticals Limited American Depositary Shares' investor relations team?

The company's listed phone number is 61-3-9093-3855 and its investor relations email address is [email protected]. The official website for Telix Pharmaceuticals Limited American Depositary Shares is www.telixpharma.com. Learn More about contacing Telix Pharmaceuticals Limited American Depositary Shares investor relations.